ASPERGILLOSIS
aspergillosisinvasive pulmonary aspergillosisIPAallergic bronchopulmonary aspergillosisABPAchronic pulmonary aspergillosisCPAaspergillomafungal ballcovid associated pulmonary aspergillosisCAPAgalactomannanbeta d glucanhalo signair crescent signvoriconazoleitraconazoleamphotericin bfungal pneumoniapost tuberculosis cavityhemoptysishypersensitivity lung diseasebronchiectasistb cavity fungustriazole antifungalsneutropenic feverimmunocompromised infectionspulmonary fungal infectionrespiratory mycosisinvasive fungal diseaseallergic fungal sinusitismucormycosis differentialfungal biomarkersBAL galactomannanaspergillus fumigatusaspergillus IgEaspergillus IgGfungal chest CTantifungal therapymedical mycologyNEET PG microbiologyNEET PG medicineDM ID exam topicsrespiratory infection high yield
Here are **30 high-yield, exam-standard, realistic ASPERGILLOSIS case scenarios** covering **ABPA, CPA, Aspergilloma, IPA, CAPA, sinus disease & disseminated forms**.
Each scenario includes **diagnostic clues + management approach**.
---
# **30 ASPERGILLOSIS CASE SCENARIOS**
---
## **1. ABPA in Asthma**
A 24-year-old asthmatic presents with recurrent wheezing, cough with brown mucus plugs, and very high IgE (2800 IU/mL). CT: central bronchiectasis.
**Diagnosis: ABPA**
**Management:** Prednisolone + itraconazole.
---
## **2. ABPA with Eosinophilia**
A 32-year-old woman with allergic rhinitis has eosinophils 1500/µL + worsening asthma. CT shows mucus impaction (“finger-in-glove”).
**Management:** Oral steroids + IgE monitoring.
---
## **3. ABPA in Cystic Fibrosis**
A 16-year-old CF patient has acute drop in lung function, fever, wheeze. Total IgE 1800 IU/mL.
**Management:** Prednisolone + itraconazole for 16 weeks.
---
## **4. Steroid-dependent Asthma with ABPA Relapse**
A patient with history of ABPA presents again with raised IgE by 40% from baseline.
**Management:** Restart steroids; evaluate for itraconazole failure.
---
## **5. Chronic Pulmonary Aspergillosis in Old TB Cavity**
A 45-year-old male treated for TB 3 years ago develops chronic cough, weight loss and cavitary thick-walled lesion. Aspergillus IgG positive.
**Diagnosis: CPA**
**Treatment:** Itraconazole 200 mg BID for 6–12 months.
---
## **6. CPA with Cavitary Lesions & Fatigue**
A smoker with COPD presents with 4-month cough and fatigue. CT: cavity with pleural thickening.
**Diagnosis:** CPA
**Management:** Oral itraconazole + 3-monthly CT.
---
## **7. CPA Not Improving on Itraconazole**
After 3 months of itraconazole, symptoms persist and drug level is subtherapeutic.
**Management:** Switch to voriconazole, therapeutic drug monitoring.
---
## **8. Aspergilloma with Mild Hemoptysis**
A 55-year-old man with past TB has recurrent mild hemoptysis. CT: mobile “fungal ball”.
**Management:** Observe; consider itraconazole only if symptomatic.
---
## **9. Massive Hemoptysis from Aspergilloma**
CT confirms a large aspergilloma in right upper lobe with active bleeding.
**Management:** Bronchial artery embolization → definitive surgical resection.
---
## **10. Invasive Aspergillosis in Neutropenia**
A 42-year-old AML patient on chemotherapy develops fever unresponsive to antibiotics. CT: halo sign. Galactomannan positive.
**Diagnosis: IPA**
**Treatment:** Voriconazole (first line).
---
## **11. IPA in Bone Marrow Transplant Patient**
A transplant recipient develops pleuritic chest pain and hemoptysis. CT halo sign.
**Management:** IV voriconazole + reduce immunosuppression.
---
## **12. ICU Patient with Ventilator-Associated IPA**
A 60-year-old ventilated patient develops worsening hypoxia. BAL galactomannan 3.0.
**Management:** Voriconazole + treat underlying sepsis.
---
## **13. Disseminated Aspergillosis – Brain Abscess**
A neutropenic patient develops seizures; MRI shows multiple ring-enhancing lesions.
**Management:** Voriconazole (excellent CNS penetration).
---
## **14. Disseminated Aspergillosis – Skin Lesions**
Painful necrotic papules in a leukemia patient. Biopsy: septate hyphae.
**Management:** IV voriconazole ± liposomal amphotericin B.
---
## **15. Disseminated Aspergillosis – Kidneys**
AKI with fungal invasion on biopsy.
**Management:** Voriconazole, consider amphotericin B if refractory.
---
## **16. COVID-Associated Pulmonary Aspergillosis (CAPA)**
A severe COVID patient on steroids develops worsening infiltrates and fever. BAL galactomannan positive.
**Management:** Voriconazole; minimize steroids.
---
## **17. CAPA with Rapid Hypoxia**
Patient worsens with extensive cavitations post-COVID.
**Management:** Switch to amphotericin B if no improvement on azoles.
---
## **18. Sinus Aspergillosis – Allergic Fungal Rhinosinusitis**
A 30-year-old allergic patient with chronic sinusitis, nasal polyps, eosinophilia. CT shows hyperdense sinus contents.
**Management:** Steroids + functional endoscopic sinus surgery (FESS).
---
## **19. Invasive Sinus Aspergillosis**
A diabetic patient with facial pain and black nasal eschars.
**Management:** Urgent debridement + IV voriconazole.
---
## **20. Aspergillus Keratitis**
Contact lens user with corneal ulcer unresponsive to antibacterials.
**Management:** Topical natamycin or voriconazole.
---
## **21. Aspergillus Endocarditis**
IV drug user with fever and negative blood cultures; echo shows vegetations.
**Management:** Amphotericin B + surgery.
---
## **22. Lung Transplant Patient – IPA**
Post-lung transplant day 30 develops cough, nodules on CT.
**Management:** Voriconazole + adjust immunosuppressants.
---
## **23. Solid-Organ Transplant – Liver**
Unexplained fever, pulmonary nodules, galactomannan positive.
**Management:** Voriconazole; consider echinocandin combo.
---
## **24. Severe Asthma with Suspected ABPA but Normal IgE**
Symptoms + bronchiectasis but IgE only mildly raised.
**Diagnosis:** Serologic ABPA variant
**Management:** Steroids + continue asthma therapy.
---
## **25. CPA with Hemoptysis in Emphysema**
Elderly smoker with CPA + intermittent hemoptysis.
**Management:** Antifungals + control COPD, consider embolization.
---
## **26. Aspergilloma in Sarcoidosis**
Sarcoid cavity filled with fungal ball, recurrent bleeding.
**Management:** Surgical resection.
---
## **27. IPA after Anti-TNF Therapy**
A patient on infliximab develops fever + nodules + pleuritic pain.
**Management:** Voriconazole; discontinue TNF blocker.
---
## **28. Post-ICU CPA**
A prior ICU patient with ARDS develops slowly progressive cavitary changes over months. IgG positive.
**Diagnosis:** Subacute invasive → CPA transition
**Management:** Oral itraconazole.
---
## **29. Aspergillus Tracheobronchitis**
Seen in ICU: pseudomembranes + ulceration in bronchi.
**Management:** Voriconazole IV.
---
## **30. Pediatric ABPA**
An 11-year-old with long-standing asthma, recurrent exacerbations, eosinophilia, IgE 2500 IU/mL.
**Management:** Prednisolone + pediatric dosing itraconazole.
---
If you want:
✅ **Hard MCQs using HTML + CSS + JS (one file)**
or
✅ **Tags for SEO**
Just say **“Give MCQs also”** or **“Give tags”**.
Below is your **complete, exhaustive, exam-ready medical note on ASPERGILLOSIS** following your preferred format (definition → pathophysiology → causes → clinical features → investigations → differentials → complete management with drug details, dosing, PK, ADRs, monitoring, counselling).
Concise but **FULLY comprehensive**.
---
# **ASPERGILLOSIS – COMPLETE MEDICAL NOTE**
---
## **1. DEFINITION**
Aspergillosis refers to a spectrum of diseases caused by **Aspergillus species**, most commonly **A. fumigatus**, affecting the lungs primarily but may disseminate in immunocompromised individuals. Disease spectrum includes:
1. **Allergic Bronchopulmonary Aspergillosis (ABPA)**
2. **Chronic Pulmonary Aspergillosis (CPA)**
3. **Aspergilloma (Fungal Ball)**
4. **Invasive Pulmonary Aspergillosis (IPA)**
5. **Disseminated Aspergillosis**
6. **Sinus Aspergillosis**
---
## **2. PATHOPHYSIOLOGY**
* **ABPA:** IgE-mediated hypersensitivity to Aspergillus colonizing bronchial tree → eosinophilia, mucus impaction, bronchiectasis.
* **CPA:** Chronic lung damage → cavity formation → slow progression ≥3 months with positive IgG.
* **Aspergilloma:** Fungal mass forms inside pre-existing lung cavity (TB, bronchiectasis, sarcoidosis).
* **IPA:** Hyphal invasion of lung tissue and blood vessels → tissue necrosis, infarction, hemoptysis → dissemination to brain, kidneys, skin.
---
## **3. RISK FACTORS**
### **For ABPA**
* Asthma (poorly controlled)
* Cystic fibrosis
* Atopy
### **For CPA / Aspergilloma**
* Post-TB cavities
* COPD
* Sarcoidosis
* Emphysema
* Immunosuppression (mild to moderate)
### **For IPA**
* Prolonged neutropenia
* Hematological malignancies
* Stem-cell / solid-organ transplantation
* Prolonged high-dose steroids
* AIDS (late stage)
* ICU + mechanical ventilation
* COVID-19 associated pulmonary aspergillosis (CAPA)
---
## **4. CLINICAL FEATURES**
### **ABPA**
* Recurrent wheezing
* Productive cough with brownish mucus plugs
* Fever
* Hemoptysis (mild)
* Central bronchiectasis
* Very high total IgE
* Asthma exacerbations
### **CPA**
* Chronic productive cough
* Weight loss
* Fatigue
* Low-grade fever
* Pleuritic chest pain
* Progressive cavitary lesions
### **Aspergilloma**
* Recurrent hemoptysis (can be massive)
* Cough
* Fungal ball visible on imaging
### **IPA**
* Fever not responding to antibiotics
* Pleuritic chest pain
* Cough
* Dyspnea
* Hemoptysis
* **CT halo sign**, **air-crescent sign**
* Multi-organ involvement if disseminated (brain, skin, kidneys, liver)
---
## **5. INVESTIGATIONS**
### **Blood**
* CBC: eosinophilia (ABPA), neutropenia (IPA)
* Serum IgE: >1000 IU/mL (ABPA)
* Aspergillus-specific IgE & IgG
* Galactomannan assay (BAL > Serum) for IPA
* β-D-glucan assay (positive in IPA)
### **Imaging**
* **Chest X-ray/CT**:
* ABPA → central bronchiectasis, “tram-track”, mucus impaction
* CPA → cavities, pleural thickening
* Aspergilloma → mobile fungal ball with air crescent
* IPA → halo sign, nodules, consolidation
### **Microbiology**
* BAL culture
* Histopathology showing acute-angle branching septate hyphae
---
## **6. DIFFERENTIAL DIAGNOSIS**
* Pulmonary TB
* Bronchiectasis (non-ABPA)
* Sarcoidosis
* Lung cancer (cavitary)
* Bacterial pneumonia
* Mucormycosis (broad, non-septate hyphae)
* Hypersensitivity pneumonitis
---
# **7. MANAGEMENT – COMPLETE**
---
## **A. ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS (ABPA)**
### **First-line Treatment**
### **1. Oral Corticosteroids**
* **Prednisolone**
**Dose:**
* 0.5–1 mg/kg/day × 2 weeks
* Taper over 3–6 months
* **MOA:** Anti-inflammatory, suppress IgE-mediated hypersensitivity
* **PK:** Hepatic metabolism, t½ 2–3 hrs
* **ADR:** Hyperglycemia, hypertension, infection risk, osteoporosis
* **Monitoring:** blood glucose, BP, weight, IgE levels monthly
* **Counselling:** do not abruptly stop, warn hyperglycemia, infection symptoms
### **2. Antifungal (to reduce antigen burden)**
* **Itraconazole** 200 mg twice daily × 16 weeks
* **MOA:** inhibits ergosterol synthesis
* **ADR:** hepatotoxicity, GI upset
* **Monitoring:** LFT baseline + every 4 weeks
* **Interactions:** CYP3A4 (statins, warfarin)
---
## **B. CHRONIC PULMONARY ASPERGILLOSIS (CPA)**
### **1. Itraconazole**
* 200 mg twice daily × 6–12 months
* Same MOA/ADR as above
### **2. Voriconazole** (if itraconazole fails)
* **Dose:**
* Loading: 6 mg/kg IV q12h × 2 doses
* Maintenance: 4 mg/kg IV q12h OR 200 mg PO q12h
* **MOA:** inhibits 14-α-demethylase
* **PK:** nonlinear metabolism, hepatic
* **ADR:** visual disturbances, hepatotoxicity, photosensitivity
* **Monitoring:** trough levels, LFTs
* **Counselling:** avoid sunlight
### **3. Surgery**
* Indicated for localized disease or severe hemoptysis
---
## **C. ASPERGILLOMA**
### **Management**
* Observation if asymptomatic
* **Massive hemoptysis → Surgical resection**
* Oral antifungals generally ineffective
* Bronchial artery embolization temporary control
---
## **D. INVASIVE PULMONARY ASPERGILLOSIS (IPA) – LIFE-THREATENING**
### **FIRST-LINE: Voriconazole**
(complete details above)
### **ALTERNATIVES**
1. **Liposomal Amphotericin B**
* **Dose:** 3–5 mg/kg/day IV
* **MOA:** binds ergosterol → membrane pore formation
* **ADR:** nephrotoxicity, hypokalemia, hypomagnesemia
* **Monitoring:** renal function, electrolytes
* **Counselling:** hydration important
2. **Isavuconazole**
* **Dose:** 372 mg IV/PO q8h × 6 doses, then daily
* **ADR:** less QT effects, hepatotoxicity
* **Use:** renally impaired patients
3. **Combination (for refractory IPA)**
* Voriconazole + Echinocandin (caspofungin)
### **Supportive Care**
* Reversal of neutropenia (G-CSF)
* Reduce steroids
* ICU ventilation support
---
## **E. DISSEMINATED ASPERGILLOSIS**
* Treat as IPA + organ-specific therapy
* Neurosurgery for abscess if needed
---
# **8. MONITORING PARAMETERS**
* IgE levels (ABPA): expect 25–35% fall
* CT chest every 3–6 months (CPA/IPA)
* LFTs for azoles
* Renal function + electrolytes for Amphotericin B
* Voriconazole trough levels: 1–5 mcg/mL
---
# **9. PATIENT COUNSELLING POINTS**
* Avoid construction sites, soil exposure
* Use N95 mask if immunocompromised
* Report visual symptoms (voriconazole)
* Avoid sunlight (phototoxicity with voriconazole)
* Ensure adherence – prolonged therapy is essential
* Monitor for jaundice, dark urine (hepatotoxicity)
---
If you want, I can also provide:
✅ **Case scenarios (10–30)**
✅ **Hard MCQs with HTML + CSS + JS in one file**
✅ **Tags for SEO or your educational site**
Just tell me:
**“Give case scenarios + MCQs also”**